IL6 and colitis: Additionally, in the experimental colitis model, miR-146a also targets receptor-interacting serine/threonine kinase 2 (RIPK2), a NOD-like receptor signaling mediator and restricts the secretion of Th17-driving cytokines from intestinal dendritic cells (DCs) and macrophages, including IL-1β, IL-6, and IL-23 [202].